These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 22929184)

  • 1. Development of the multi-attribute Adolescent Health Utility Measure (AHUM).
    Beusterien KM; Yeung JE; Pang F; Brazier J
    Health Qual Life Outcomes; 2012 Aug; 10():102. PubMed ID: 22929184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caregiver experiences and observations of intrathecal idursulfase-IT treatment in a phase 2/3 trial in pediatric patients with neuronopathic mucopolysaccharidosis II.
    Yee KS; Lewis S; Evans E; Romano C; Alexanderian D
    Orphanet J Rare Dis; 2024 Mar; 19(1):110. PubMed ID: 38462612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome).
    Muenzer J; Wraith JE; Beck M; Giugliani R; Harmatz P; Eng CM; Vellodi A; Martin R; Ramaswami U; Gucsavas-Calikoglu M; Vijayaraghavan S; Wendt S; Puga AC; Ulbrich B; Shinawi M; Cleary M; Piper D; Conway AM; Kimura A
    Genet Med; 2006 Aug; 8(8):465-73. PubMed ID: 16912578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
    da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
    Cochrane Database Syst Rev; 2014 Jan; (1):CD008185. PubMed ID: 24399699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
    da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
    Cochrane Database Syst Rev; 2011 Nov; (11):CD008185. PubMed ID: 22071845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome).
    Muenzer J; Gucsavas-Calikoglu M; McCandless SE; Schuetz TJ; Kimura A
    Mol Genet Metab; 2007 Mar; 90(3):329-37. PubMed ID: 17185020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation of a valuation function for a diabetes mellitus-specific preference-based measure of health: the Diabetes Utility Index.
    Sundaram M; Smith MJ; Revicki DA; Miller LA; Madhavan S; Hobbs G
    Pharmacoeconomics; 2010; 28(3):201-16. PubMed ID: 20151725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with Hunter syndrome.
    Sohn YB; Cho SY; Lee J; Kwun Y; Huh R; Jin DK
    Mol Genet Metab; 2015 Feb; 114(2):156-60. PubMed ID: 25219292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A post hoc analysis of Projected Retained Ability Scores (PRAS) for the longitudinal assessment of cognitive functioning in patients with neuronopathic mucopolysaccharidosis II receiving intrathecal idursulfase-IT.
    Yee KS; Chirila C; Davenport E; Mladsi D; Barnett C; Kronenberger WG
    Orphanet J Rare Dis; 2023 Nov; 18(1):343. PubMed ID: 37915038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valuing Treatments for Parkinson Disease Incorporating Process Utility: Performance of Best-Worst Scaling, Time Trade-Off, and Visual Analogue Scales.
    Weernink MG; Groothuis-Oudshoorn CG; IJzerman MJ; van Til JA
    Value Health; 2016; 19(2):226-32. PubMed ID: 27021757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study.
    Guffon N; Heron B; Chabrol B; Feillet F; Montauban V; Valayannopoulos V
    Orphanet J Rare Dis; 2015 Apr; 10():43. PubMed ID: 25887606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase.
    Barbier AJ; Bielefeld B; Whiteman DA; Natarajan M; Pano A; Amato DA
    Mol Genet Metab; 2013 Nov; 110(3):303-10. PubMed ID: 23988379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preferences for health outcomes and cost-utility analysis.
    Torrance GW
    Am J Manag Care; 1997 May; 3 Suppl():S8-20. PubMed ID: 10180342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical study of enzyme replacement therapy with idursulfase].
    Gutiérrez-Solana LG
    Rev Neurol; 2007 Feb; 44 Suppl 1():S7-S11. PubMed ID: 17345556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical response to long term enzyme replacement treatment in children, adolescent and adult patients with Hunter syndrome.
    Dalmau Serra J; Vitoria Miñana I; Calderón Fernández R; Cortell Aznar I
    Med Clin (Barc); 2015 Nov; 145(9):392-8. PubMed ID: 26360015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using the Analytic Hierarchy Process to Derive Health State Utilities from Ordinal Preference Data.
    Reddy BP; Adams R; Walsh C; Barry M; Kind P
    Value Health; 2015 Sep; 18(6):841-5. PubMed ID: 26409612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health State Utilities for Patient's Current Health from Bipolar Type I Disorder.
    Banihashemian M; Rashidian A; Gholamian F; Parsaeian M; Moradi N; Amini H
    J Ment Health Policy Econ; 2018 Mar; 21(1):3-10. PubMed ID: 29643263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS).
    Burton BK; Jego V; Mikl J; Jones SA
    J Inherit Metab Dis; 2017 Nov; 40(6):867-874. PubMed ID: 28887757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimation of utilities in attention-deficit hyperactivity disorder for economic evaluations.
    Lloyd A; Hodgkins P; Sasane R; Akehurst R; Sonuga-Barke EJ; Fitzgerald P; Nixon A; Erder H; Brazier J
    Patient; 2011; 4(4):247-57. PubMed ID: 21995830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome).
    Pano A; Barbier AJ; Bielefeld B; Whiteman DA; Amato DA
    Orphanet J Rare Dis; 2015 Apr; 10():50. PubMed ID: 25902842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.